Abcellera Biologics Inc ABCL

$14.59 -0.23 (-1.55%)

Valuation

Market cap
4,543,975,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
4,856,900
Avg volume
6,959,834
Day's range
$14.56 – $15.02
Shares out
306,611,000
Stochastic %K
87%
Beta
1.32
Analysts
Strong Sell
Price target
$16.70

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

abcluv Oct 1, 1:20 PM
$ABCL I sold some this morning hoping to buy back more later. But I’ll reinvest the funds here no matter which way it moves. I’m sure you all were wondering.
0 replies
psyxopathis Oct 1, 1:15 PM
$ABCL https://www.abcellera.com/publications/top-line-results-of-a-phase-2-study-of-abcl635-a-first-in-class-nk3r-monoclonal-antibody-for-the-treatment-of-vasomotor-symptoms
0 replies
Odoji Oct 1, 12:59 PM
$ABCL 💉
0 replies
Fjordvei Oct 1, 12:29 PM
$ABCL probably selling today from my 4.7 average. been a good ride
1 replies
Plan2TradeTrade2Plan Oct 1, 4:36 AM
$ABCL https://investingnews.com/abcellera-announces-presentation-of-phase-2-data-for-abcl635-at-the-ims-world-congress-on-menopause-2026/ 7:30am EST
1 replies
beestMod516 Oct 1, 1:33 AM
$IBRX vs $ABCL vs $MRNA Pick your poison.
2 replies
officialstephenkalayjian Oct 1, 12:39 AM
🚨 $ABCL WATCHING FOR A BREAKOUT 📈 Price: $14.59 📊 Volume: Average or below 🔥 Catalyst: Recent partnership buzz around AbCellera's antibody discovery pipeline is keeping speculative interest alive. 🎯 Resistance: $16.20 🛡️ Support: $13.40 Bull case: A move through $16.20 on rising volume could spark momentum back toward the $18 zone. Bear case: A breakdown below $13.40 support risks a slide back toward the $12 range. 👀 What I'm watching: Need volume to pick up meaningfully to confirm any directional move here. Note: I’m not a financial advisor or a market predictor, and I don’t offer any premium subscriptions or paid services. Feel free to stay connected with me @officialstephenkalayjian and checkout my bio link.
0 replies
Plan2TradeTrade2Plan Sep 30, 10:56 PM
$ABCL may need a miracle tomorrow, the way things are going tonight.
1 replies